CURATIS N AG (SW:CURN) — Market Cap & Net Worth
Market Cap & Net Worth: CURATIS N AG (CURN)
CURATIS N AG (SW:CURN) has a market capitalization of $89.64 Million (CHF70.90 Million) as of June 16, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #19727 globally and #190 in its home market, demonstrating a 6.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CURATIS N AG's stock price CHF24.30 by its total outstanding shares 5151693 (5.15 Million). Review CURN current and long-term liabilities to assess the company's total debt and financial obligations.
CURATIS N AG Market Cap History: 2015 to 2026
CURATIS N AG's market capitalization history from 2015 to 2026. Data shows change from $1.17 Billion to $158.27 Million (-17.09% CAGR).
CURATIS N AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CURATIS N AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.28x
CURATIS N AG's market cap is 12.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.17 Billion | $15.59 Million | -$1.63 Million | 74.85x | N/A |
| 2016 | $875.36 Million | $17.94 Million | -$1.02 Million | 48.78x | N/A |
| 2017 | $875.36 Million | $17.55 Million | -$260.00K | 49.87x | N/A |
| 2018 | $320.97 Million | $16.19 Million | -$762.00K | 19.82x | N/A |
| 2019 | $496.04 Million | $17.30 Million | -$940.00K | 28.67x | N/A |
| 2020 | $2.36 Billion | $4.11 Million | -$16.00K | 575.20x | N/A |
| 2024 | $84.67 Million | $6.90 Million | -$4.34 Million | 12.28x | N/A |
Competitor Companies of CURN by Market Capitalization
Companies near CURATIS N AG in the global market cap rankings as of June 16, 2026.
Key companies related to CURATIS N AG by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
CURATIS N AG Historical Marketcap From 2015 to 2026
Between 2015 and today, CURATIS N AG's market cap moved from $1.17 Billion to $ 158.27 Million, with a yearly change of -17.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF158.27 Million | +102.50% |
| 2025 | CHF78.16 Million | -7.69% |
| 2024 | CHF84.67 Million | +625.45% |
| 2023 | CHF11.67 Million | -96.49% |
| 2022 | CHF332.64 Million | -85.19% |
| 2021 | CHF2.25 Billion | -4.94% |
| 2020 | CHF2.36 Billion | +376.47% |
| 2019 | CHF496.04 Million | +54.55% |
| 2018 | CHF320.97 Million | -63.33% |
| 2017 | CHF875.36 Million | 0.00% |
| 2016 | CHF875.36 Million | -25.00% |
| 2015 | CHF1.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of CURATIS N AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $89.64 Million USD |
| MoneyControl | $89.64 Million USD |
| MarketWatch | $89.64 Million USD |
| marketcap.company | $89.64 Million USD |
| Reuters | $89.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more